You are here: Industry Insights > Sangamo Therapeutics

News List

Sangamo, Pfizer announce updated Phase 1/2 results for SB-525 investigational Hemophilia A gene therapy biospectrumasia
July 08, 2019
In addition to the collaboration for the development and commercialization of gene therapies for hemophilia A, Sangamo and Pfizer are also working together on the development of gene therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal lob
Gene therapy biotech shares sink on inconclusive trial results pharmaphorum
February 14, 2019
Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results in early clinical trials.
Sangamo strikes TxCell takeover to gain CAR-Treg pipeline fiercebiotech
July 26, 2018
Sangamo Therapeutics is set to acquire TxCell for its CAR-Treg platform and pipeline. The €72 million ($84 million) takeover will position Sangamo to move a CAR-carrying regulatory T cell candidate into testing in solid organ transplant patients next year
Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia biospace
April 28, 2018
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the California Institute for Regenerative Medicine (CIRM) has awarded an $8 million grant for Sangamo to evaluate ST-400
Recent Hack of Sangamo Therapeutics Exec Underlines Increased Risk for Biopharma biospace
April 19, 2018
Sangamo Therapeutics, based in Richmond, California, recently filed a notice with the U.S. Securities and Exchange Commission (SEC) describing a data security breach.
Sangamo Therapeutics Announces Special Regulatory Designations from the FDA americanpharmaceuticalreview
May 05, 2017
Sangamo Therapeutics announced it has received special regulatory designations for three of the company’s clinical programs from the U.S. Food and Drug Administration (FDA).